ResMed Price to Free Cash Flow Ratio 2010-2024 | RMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

ResMed average price to free cash flow ratio for 2024 was 24.93, a 45.56% increase from 2023.
ResMed average price to free cash flow ratio for 2023 was 45.79, a 60.09% decline from 2022.
ResMed average price to free cash flow ratio for 2022 was 114.73, a 74.39% decline from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

ResMed average price to free cash flow ratio for 2024 was 24.93, a 45.56% increase from 2023.
ResMed average price to free cash flow ratio for 2023 was 45.79, a 60.09% decline from 2022.
ResMed average price to free cash flow ratio for 2022 was 114.73, a 74.39% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$194.8B
Boston Scientific (BSX)	$139.8B
Stryker (SYK)	$139.4B
EssilorLuxottica (ESLOY)	$110.1B
Medtronic (MDT)	$103.4B
Lonza Group Ag (LZAGY)	$43.7B
Haleon (HLN)	$41.2B
GE HealthCare Technologies (GEHC)	$38.7B
Terumo (TRUMY)	$28B
Koninklijke Philips (PHG)	$24.3B
Zimmer Biomet Holdings (ZBH)	$20.8B
Insulet (PODD)	$19.1B
Baxter (BAX)	$15B
Smith & Nephew SNATS (SNN)	$10.5B
Bio-Rad Laboratories (BIO)	$9.6B
BellRing Brands (BRBR)	$9.1B
Demant (WILYY)	$8.6B
Lantheus Holdings (LNTH)	$6.7B
Haemonetics (HAE)	$3.9B
ICU Medical (ICUI)	$3.8B
Prestige Consumer Healthcare (PBH)	$3.7B
Perrigo (PRGO)	$3.3B
Envista Holdings (NVST)	$3.2B
QuidelOrtho (QDEL)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
Neogen (NEOG)	$2.7B
GN Store Nord (GNNDY)	$2.6B
LeMaitre Vascular (LMAT)	$2.1B
Green Thumb Industries (GTBIF)	$1.6B
AtriCure (ATRC)	$1.5B